China is promoting high-level opening-up in the financial sector and welcomes foreign-invested enterprises to deepen mutually-beneficial ...

The 15th China International Aviation and Aerospace Exhibition, also known as Airshow China, kicked off in Zhuhai of south ...

The UN on Tuesday warned that already low levels of aid trickling into Gaza had dwindled further, with the situation in the besieged north ...

A Moscow court on Tuesday sentenced a paediatrician to five-and-a-half years in prison for criticising the Ukraine campaign during a private appointment, after she was denounced by the ex-wife of a ...

China and Russia held the 19th round of their annual strategic security consultation in Beijing on Tuesday, with both sides exchanging in-depth ...

Vietnamese electric vehicle maker VinFast will receive $3.5 billion in new funding, the majority from its CEO Pham Nhat Vuong, parent group ...

Nearly four million German workers in the key electrical and metalworking sectors will receive pay increases after the country's biggest trade union ...

Two environmental groups kick off a legal challenge in Scotland on Tuesday to block the Rosebank and Jackdaw oil and gas fields in the North ...

Mauritius opposition leader Navin Ramgoolam declared on Tuesday that his alliance had won a crushing election victory over the ruling coalition, after Prime Minister Pravind Jugnauth conceded he faced ...

This advanced biotechnology offers a level of protection that is truly unparalleled.” Supported by the Taiwan government’s ...

這項III期臨床試驗是一項在中國開展的隨機、雙盲、安慰劑對照、多中心的臨床試驗，旨在評估ASC40每日一次口服片治療中、重度尋常性痤瘡的安全性和療效。480例中、重度尋常性痤瘡患者按照1:1的比例被隨機分至一個活性藥物組和一個安慰劑對照組，接受每日 一次50毫克 ASC40口服片或匹配的安慰劑治療，為期12周。頂線結果預計將於2025年第2季度公佈。

Altair software available to organizations through ESA Partnership Initiative for Commercialisation (EPIC) ...